学术探索
学术期刊
新闻热点
数据分析
智能评审

Oral contraceptives and the risk of venous thrombosis.

被引：370
作者：
Vandenbroucke, JP
Rosing, J
Bloemenkamp, KWM
Middeldorp, S
Helmerhorst, FM
Bouma, BN
Rosendaal, FR
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Obstet Gynecol & Reprod Med, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Thrombosis Haemostasis Res Ctr, NL-2300 RC Leiden, Netherlands
[4] Univ Limburg, Cardiovasc Res Inst, Dept Biochem, NL-6200 MD Maastricht, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[6] Univ Utrecht Hosp, Dept Hematol, Thrombosis & Hemostasis Lab, Utrecht, Netherlands
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2001年 / 344卷 / 20期
关键词：
D O I：
10.1056/NEJM200105173442007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1527 / 1535
页数：9
相关论文
共 100 条
[1]  
Akhter H, 1998, WHO TECH REP SER, V877, P1
[2]   Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism [J].
Andersen, BS ;
Olsen, J ;
Nielsen, GL ;
Steffensen, FH ;
Sorensen, HT ;
Baech, J ;
Gregersen, H .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (01) :28-31
[3]   RECURRENCE OF VENOUS THROMBOEMBOLIC DISEASE AND USE OF ORAL-CONTRACEPTIVES [J].
BADARACC.MA ;
VESSEY, MP .
BRITISH MEDICAL JOURNAL, 1974, 1 (5901) :215-217
[4]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[5]   The safety of third-generation oral contraceptives [J].
Barbieri, RL ;
Speroff, L ;
Walker, AM ;
McPherson, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (06) :1822-1823
[6]   Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism [J].
Bennet, L ;
Odeberg, H .
JOURNAL OF INTERNAL MEDICINE, 1998, 244 (01) :27-32
[7]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[8]   Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias [J].
Bloemenkamp, KWM ;
Rosendaal, FP ;
Büller, HR ;
Helmerhorst, FM ;
Colly, LP ;
Vandenbroucke, JP .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) :65-70
[9]   Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects [J].
Bloemenkamp, KWM ;
Rosendaal, FR ;
Helmerhorst, FM ;
Vandenbroucke, JP .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :49-52
[10]   ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].
BLOEMENKAMP, KWM ;
ROSENDAAL, FR ;
HELMERHORST, FM ;
BULLER, HR ;
VANDENBROUCKE, JP .
LANCET, 1995, 346 (8990) :1593-1596
12345678910